Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CD74 | P04233 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165168 | 0.83 | HPGDS (0.61) | RAB9ATP53ALDH1A1KDM4EMAPT | |
| SCHEMBL20282062 | 0.83 | HPGDS (0.57) | RAB9ATP53ALDH1A1KDM4EMAPT | |
| SCHEMBL8085746 | 0.80 | HPGDS (0.68) | RAB9ATP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL27337757 | 0.80 | KMT2A (0.69) | RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL6165131 | 0.79 | TP53 (0.55) | RAB9ATP53SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16799801 | 0.78 | HPGDS (0.54) | RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL6167298 | 0.78 | ALDH1A1 (0.58) | RAB9ATP53SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL6669062 | 0.76 | RAB9A (0.75) | RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL18586308 | 0.76 | ALKBH1 (0.54) | RAB9ATP53SMN1; SMN2NPC1ALKBH1 | |
| SCHEMBL22580254 | 0.76 | TP53 (0.58) | RAB9ATP53ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| EP-1379511-A1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | RAB9A 1379/4885TP53 4859/4885SMN1; SMN2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.